Reports Q4 revenue $498M, consensus $486.5M. "Our solid results for the fourth quarter of 2022 closed out another year with a strong performance driven by continued execution in double-digit CER sales growth of our non-COVID product groups coupled with delivering on improvements in our Sample to Insight portfolio," said Thierry Bernard, CEO. "We saw broad-based strength during 2022 across our balanced activities serving customers in Life Sciences and Molecular Diagnostics and in many countries around the world. We are especially pleased with the progress in our Five Pillars of Growth strategy, which also involves focusing our portfolio on areas with significant growth potential. We have positioned QIAGEN to navigate a volatile macro environment in 2023 and continue to focus on the growth of the non-COVID product portfolio that positions QIAGEN well for the future."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on QGEN:
- Singular Genomics showcases G4 sequencing data with 11 genomics partners
- Genetic Technologies forms strategic alliance with Qiagen
- Qiagen Mulls Stake Sale in Bioinformatics Unit
- Qiagen mulls selling stake in $1B bioinformatics division, Bloomberg reports
- Qiagen weighing sale of stake in $1B bioinformatics unit, Bloomberg says
